What is happening with clinical trials in the UK as we slowly emerge from COVID-19, and how can you continue to support clinical research into new treatment options? The last year has seen intense focus on the development of treatments and vaccines for COVID-19, along with respiratory clinicians continuing to
The COVID-19 pandemic is a global emergency. Identifying populations who are at risk of severe complications is crucial in developing special measures to prevent or reduce severe illness and mortality in vulnerable patients. Emerging evidence indicates that alpha1-proteinase inhibitor might inhibit infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). α1-Antitrypsin
We were pleased to announce back in August 2020 that the first person was dosed with ZF874, a potential treatment for alpha-1-antitrypsin deficiency. Then on the 24th September we published the details for HMR who are running the trail on behalf of Z Factor, asking for PiMZ people to help.
18th October 2020 Professor Gerry McElvaney (left), the study’s senior author and a consultant in Beaumont Hospital, and Professor Ger Curley (right) stand in front of the RCSI Education and Research Centre in Beaumont Hospital, Dublin. Scientists have developed, for the first time, a score that can accurately predict
15th October 2020 Vertex Pharmaceuticals announced that based on early data of its Phase II trial of VX-814 in Alpha-1 antitrypsin deficiency (AATD), it is halting the trial and ending development of the drug. AATD is a genetic disease resulting in a missing liver protein. Children with AATD either do not produce